Pepcid Marketing Strategy To Stay Unchanged In Face Of Prilosec 1 Launch
This article was originally published in The Tan Sheet
J&J/Merck has no plans to change the marketing strategy behind its Pepcid line of heartburn products, despite the probable upcoming launch of an OTC version of Prilosec
You may also be interested in...
Possible long-term use of omeprazole to prevent chronic heartburn or gastroesophageal reflux disease (GERD) is acceptable, despite an OTC indication for only 14-day use, FDA advisory committee members determined at a meeting in Bethesda, Md. June 21
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning